Alzheimer’s Research UK Announces Record £9.5m Investment in Dementia Studies
Alzheimer’s Research UK has announced its largest ever single funding round, committing £9.5 million to 25 new research projects across the United Kingdom in a move that charity officials say will significantly accelerate progress in the understanding, diagnosis and treatment of dementia.
The investment, made possible through charitable donations, brings the organisation’s cumulative spending on dementia research to more than £270 million since its first grant award in 1998. Over that period, the charity has supported in excess of 1,450 projects and engaged more than 3,400 researchers collaborating with scientists across more than 110 countries.
The 25 newly funded projects span the full research pipeline, from exploratory early-stage studies to clinical research aimed at bringing potential treatments closer to patients — a category particularly relevant to those working in residential and nursing care settings, where dementia remains one of the most prevalent and complex conditions facing residents and staff alike.
In February, the charity invested more than £680,000 across ten Pilot Projects designed to provide short-term funding for high-potential ideas at an early stage of development. Among these is a project led by Dr Scott Miners at the University of Bristol, which is using advanced 3D imaging to examine how blood vessels in the brain change across different forms of dementia, including Alzheimer’s disease and vascular dementia. The research aims to deepen understanding of how vascular damage contributes to disease progression and to support the development of more effective treatments and preventative approaches.
A further £4 million has been directed through the charity’s Major Project scheme, which funds large-scale studies addressing complex, long-standing questions in dementia research. One such project, led by Dr Anto Praveen Rajkumar Rajamani at the University of Nottingham, is working to refine a blood test capable of distinguishing dementia with Lewy bodies from Alzheimer’s disease — two conditions that can present similarly but require different approaches to care and treatment. Using blood biomarkers and artificial intelligence, the team aims to reduce rates of misdiagnosis among NHS patients, enabling more people to receive an accurate diagnosis and appropriate support sooner.
A newly established Clinical Committee has awarded £2.6 million to fund six Clinical Fellowships, investing in the next generation of dementia clinical research leaders. The committee, which brings together leading clinicians, scientists and people with lived experience of dementia, will provide independent expert oversight to strengthen the UK’s clinical research capacity in this field. Further details of the fellowship awards are expected to be announced separately.
For care home providers and professionals, developments of this nature carry particular significance. Earlier and more accurate diagnosis, improved understanding of disease mechanisms, and the eventual development of new treatments all have direct implications for the quality of care that can be offered to residents living with dementia.
